|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.05 / 9.72|
-Preclinical Data Presented at the 28th EORTC-NCI-AACR Symposium-
The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.
Conference Call Scheduled for November 14, 2016 at 4:30 p.m. ET
In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.51 on the day. This compares to an average yield of 10.90% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.
Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.
H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.
Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT
Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations
Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT
Preclinical Data Presented at the AACR 2016 Meeting
-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --
Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc.
Company to Present at the Biotech Showcase(TM) 2016 Conference
In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting